Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Long acting beta-adrenoceptor agonist Stories

2014-01-27 16:25:06

WINSTON-SALEM, N.C., Jan. 27, 2014 /PRNewswire-USNewswire/ -- More than 25 million people in the United States have asthma, a chronic lung disease that inflames and narrows the airways causing recurring periods of wheezing, chest tightness, shortness of breath and coughing. (Logo: http://photos.prnewswire.com/prnh/20111114/DC06171LOGO) Although several types of drugs are available to treat asthma, long-acting beta agonists (LABAs) are among the most commonly used and work well for...

2014-01-27 14:57:08

More than 25 million people in the United States have asthma, a chronic lung disease that inflames and narrows the airways causing recurring periods of wheezing, chest tightness, shortness of breath and coughing. Although several types of drugs are available to treat asthma, long-acting beta agonists (LABAs) are among the most commonly used and work well for most people. However, for a small subgroup of people with asthma, LABAs can cause severe, life-threatening side effects and carry a...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-12-12 10:33:22

A new guideline has provided an updated definition of severe asthma along with new recommendations for treating the condition. Produced by a joint task force of the European Respiratory Society and the American Thoracic Society, the guideline is published online today (12 December 2013) in the European Respiratory Journal. Although severe asthma is estimated to account for less than 10% of all asthmatics, these patients have the greatest burden and require a disproportionate amount of...

2013-11-27 15:20:34

A popular combination asthma therapy dogged by safety concerns has not harmed British Columbians and should remain in use, according to researchers at the University of British Columbia and Vancouver Coastal Health Research Institute. The therapy combines an inhaled corticosteroid to reduce swelling in the airways with "long-acting beta agonists" (LABAs) to ease breathing and reduce the risk of a severe asthma attack. The U.S. Food and Drug Administration (FDA), reacting to claims that...

2013-11-11 08:28:31

Resources Available to Help Take Control WILMINGTON, Del., Nov. 11, 2013 /PRNewswire/ -- For many Americans, breathing is a challenge. Over 12 million have chronic obstructive pulmonary disease (COPD)( )and live with symptoms, including constant coughing, wheezing, and shortness of breath. But with an additional 12 million Americans remaining undiagnosed, recognizing COPD signs and symptoms and seeking help is an important health priority. To view the multimedia assets associated with this...

2013-10-30 12:25:42

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta(2)-agonist (LABA),...

2013-10-24 16:27:17

Eleven presentations on investigational compounds and an approved product will be presented at the CHEST 2013 meeting RIDGEFIELD, Conn., Oct. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced the upcoming presentation of data from 11 abstracts, including 6 oral presentations, across the company's respiratory portfolio at the 2013 American College of Chest Physicians (ACCP) annual meeting, CHEST 2013, taking place October 26 - 31 in Chicago. These data exemplify...

2013-09-09 08:28:07

DORVAL, QC, Sept. 9, 2013 /CNW/ - Novartis announced new analyses of data for investigational QVA149 (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed clinically significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus those comparators evaluated in the study(1,2).( )These data were part of 39...

2013-09-08 20:20:26

Phase 3 results presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 RIDGEFIELD, Conn., Sept. 8, 2013 /PRNewswire/ -- Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 mcg delivered once daily via the Respimat(®) inhaler provided improvements in lung function in patients with moderate to very severe...